NCT03886987

Brief Summary

Skin Sensitization Test (Modified Draize-95 Test) to Support a Low Dermatitis Potential Claim for a Blue Non Sterile Powder Free Nitrile Examination Gloves. This study is a RIPT (Repeat Insult Patch Test) to evaluate whether residual chemical additives at the level that may induce Type IV allergy in the nonsensitized general user population are present in a finished Blue Non Sterile Powder Free Nitrile Examination Glove.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
245

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 2, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 8, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 8, 2018

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

March 18, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 22, 2019

Completed
Last Updated

March 22, 2019

Status Verified

March 1, 2019

Enrollment Period

2 months

First QC Date

March 18, 2019

Last Update Submit

March 21, 2019

Conditions

Keywords

Modified Draize-95 TestSkin SensitisationRepeat Insult Patch Test

Outcome Measures

Primary Outcomes (1)

  • Irritation scored by Erythemal Scoring Scale

    Basic Score and Description: 0 - No visible reaction. 0.5 - Doubtful or negligible erythema reaction. 1.0 - Mild or just perceptible macular erythema reaction in a speckled/follicular, patchy or confluent pattern (slight pinking). 2.0 - Moderate erythema reaction in a confluent pattern (definite redness). 3.0 - Strong or brisk erythema reaction that may spread beyond the test site. If a subject develops a positive reaction (a score value of 1.5) to the test material or shows signs of irritation after patch applications, further patching on those individuals are stopped. In order to qualify for the claim of a reduced sensitization potential, all 200 individuals completing the study should exhibit a score value of no more than 1.5 based on the scoring criteria.

    8 weeks

Study Arms (1)

Device and Control

EXPERIMENTAL

Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact. Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml Negative control: Blank patch Dose: Not applicable

Device: Blue Non Sterile Powder Free Nitrile Examination Gloves

Interventions

Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.

Device and Control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects must be aged 18 to 65 years, inclusive;
  • Subjects who have not participated in other voluntary testing for at least 30 days;
  • Subjects must execute an Informed Consent Form that includes a HIPAA statement; and
  • Subjects must be capable of understanding and following directions.
  • Female subjects must produce a negative urine pregnancy test prior to the initiation and also at the completion of the trial.

You may not qualify if:

  • Subjects who are in ill health, as determined by the PI;
  • Subjects who are taking medication, other than birth control, which could influence the purpose, integrity or outcome of the trial;
  • Subjects who have used topical or systemic corticosteroids, anti-inflammatories, antihistamines or antibiotics within 2 weeks prior to trial initiation or during their participation on this trial;
  • Female subjects who are pregnant as evidenced by a urine pregnancy test, planning to become pregnant or lactating during the trial;
  • Subjects who have a history of adverse reactions to cosmetics, OTC drugs, or other personal care products;
  • Subjects who introduce the use of any new cosmetic, toiletry or personal care products during the trial;
  • Subjects with any visible skin disease that might be confused with skin reactions caused by the test material;
  • Subjects with any knowledge or indication of existing Type IV allergy (delayed hypersensitivity) to natural rubber chemical additives;
  • Subjects with any indication of existing Type I allergy (immediate hypersensitivity) to natural rubber proteins;
  • Subjects with a history of frequent irritation; or
  • Subjects who have received endogenous or exogenous immunosuppressive treatment (or prolonged exposure to sun).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Consumer Product Testing Company, Inc.

Fairfield, New Jersey, 07004, United States

Location

Study Officials

  • Michael Caswell, Ph.D., CCRA, CCRC

    Consumer Product Testing Company, Inc.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Model Details: Blue Non Sterile Powder Free Nitrile Examination Gloves Dose: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact. Positive control: 0.4% sodium lauryl sulfate (SLS) Dose: 0.2 ml Negative control: Blank patch Dose: Not applicable
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 18, 2019

First Posted

March 22, 2019

Study Start

April 2, 2018

Primary Completion

June 8, 2018

Study Completion

June 8, 2018

Last Updated

March 22, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will not share

Locations